Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Testa

Showing results (371-380 of 588) with videos related to

Pageof 59
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2010
GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated AktDeborah A Altomare, Lili Zhang, Jing Deng, et al.
Cancer Research|May 15, 1994
Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexityJ R Testa, L A Getts, H Salazar, et al.
The Italian Journal of Gastroenterology|February 1, 1990
Analysis of circadian fluctuations of bile salt concentration and pH in the stomach of normal subjects and patients suspected of having duodenogastric refluxV Savarino, R Testa, G S Mela, et al.
Diabetes, Nutrition & Metabolism|December 4, 2004
Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patientsR Testa, A R Bonfigli, C Sirolla, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part IA Leonardi, J P Hieble, L Guarneri, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 21, 2001
In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic alpha1A- vs. alpha1B- and alpha1D-adrenoceptorsM Eltze, R Boer, M C Michel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 23, 1997
Prognostic value of specific KRAS mutations in lung adenocarcinomasJ M Siegfried, A T Gillespie, R Mera, et al.
Prostate Cancer and Prostatic Diseases|September 3, 2020
Immortalization of human primary prostate epithelial cells via CRISPR inactivation of the CDKN2A locus and expression of telomeraseZiran Zhao, Holly Fowle, Henkel Valentine, et al.
Cardiovascular Research|September 25, 1998
Super-normal 201Tl retention in hibernating myocardium: an ex-vivo study using the failing human heartO Parodi, R De Maria, R Testa, et al.
International Journal of Environmental Research and Public Health|April 12, 2022
Asbestos and Other Hazardous Fibrous Minerals: Potential Exposure Pathways and Associated Health RisksTerri-Ann Berry, Elena Belluso, Ruggero Vigliaturo, et al.
Pageof 59

Showing results (371-380 of 588) with videos related to

Sort By:
Pageof 59
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2010
GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated AktDeborah A Altomare, Lili Zhang, Jing Deng, et al.
Cancer Research|May 15, 1994
Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexityJ R Testa, L A Getts, H Salazar, et al.
The Italian Journal of Gastroenterology|February 1, 1990
Analysis of circadian fluctuations of bile salt concentration and pH in the stomach of normal subjects and patients suspected of having duodenogastric refluxV Savarino, R Testa, G S Mela, et al.
Diabetes, Nutrition & Metabolism|December 4, 2004
Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patientsR Testa, A R Bonfigli, C Sirolla, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part IA Leonardi, J P Hieble, L Guarneri, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 21, 2001
In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic alpha1A- vs. alpha1B- and alpha1D-adrenoceptorsM Eltze, R Boer, M C Michel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 23, 1997
Prognostic value of specific KRAS mutations in lung adenocarcinomasJ M Siegfried, A T Gillespie, R Mera, et al.
Prostate Cancer and Prostatic Diseases|September 3, 2020
Immortalization of human primary prostate epithelial cells via CRISPR inactivation of the CDKN2A locus and expression of telomeraseZiran Zhao, Holly Fowle, Henkel Valentine, et al.
Cardiovascular Research|September 25, 1998
Super-normal 201Tl retention in hibernating myocardium: an ex-vivo study using the failing human heartO Parodi, R De Maria, R Testa, et al.
International Journal of Environmental Research and Public Health|April 12, 2022
Asbestos and Other Hazardous Fibrous Minerals: Potential Exposure Pathways and Associated Health RisksTerri-Ann Berry, Elena Belluso, Ruggero Vigliaturo, et al.
Pageof 59